Enterococcus faecalis 2001, a probiotic lactic acid bacterium can inhibit the growth of tumors, reveals a new study.
The research team has used Enterococcus faecalis 2001 as a biological response modifier (BRM).
From physiological limitation of bacterial preservation in storage and safety, the live E. faecalis 2001 has been heat-treated and the BRM components containing high level of £]-glucan, named EF-2001, were prepared.
Lymphocyte versus polymorphonuclear leukocyte ratio was increased in mice upon treatment with EF-2001. The number of lymphocytes was increased in the EF-2001-treated group.
In the mice bearing two different Ehrlich solid and Sarcoma-180 carcinomas, the treatment with EF-2001 resulted in anti-tumor action.
Tumor-suppressive capacity upon treatment with EF-2001 was significantly increased compared to normal controls.
During the time interval administration of 5 weeks between the priming and secondary administration of EF-2001, the expression and production levels of TNF-£\ were also observed in the EF-2001 administered mice.
Additionally, anti-tumor activity examined with the intravenous administration of EF 2001 with a 34 time intervals was also observed, as the growth of Sarcoma-180 cells was clearly inhibited by the EF-2001.
From the results, it was suggested that the immune response is enhanced due to antioxidative activity caused by the EF-2001 and anti-tumor activity by NK cells and TNF-£\.